After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified 5 direct (antigen/RNA) tests for detection of acute infection and 6 indirect (antibody) tests for detection of prior infection that meet the recently published World Health Organization (WHO) “desirable” Target Product Profile (TPP) criteria. The researchers hope their work will help communities and healthcare systems make more informed decisions when choosing rapid, point-of-care COVID-19 tests.
Image by Gerd Altmann from Pixabay
TPPs outline the desired characteristics of a product aimed at a specific disease. The WHO TPPs can be used to compare key features of COVID-19 tests and select products that best respond to the public health needs of each region.
Share this article
Share this article
TACOMA, Wash., Jan. 6, 2021 /PRNewswire/ GenCare Lifestyle, which operates six assisted living and retirement communities in the Puget Sound has launched the first-of-its-kind on-site, rapid testing for Covid-19 and flu with the ability to understand initial results within 15-30 minutes.
The rapid test program administered by CAIPHI EP Testing mobile testing teams can provide results within minutes at each of GenCare s six assisted living communities. The new rapid tests and the provision of Covid-19 vaccines at the communities in coming weeks are part of GenCare s ongoing efforts to keep its communities safe and reduce the spread of the Covid-19 virus.